跳至主要内容
临床试验/NCT00351546
NCT00351546已完成3 期

A Study to Assess the Effects of DPP-4 Inhibition on Insulin Sensitivity in Type 2 Diabetes

Novartis0 个研究点目标入组 12 人开始时间: 2005年2月1日最近更新:
适应症
相关药物

试验速览

阶段
3 期
状态
已完成
发起方
Novartis
入组人数
12
主要终点
Effect on insulin sensitivity at 6 weeks

研究概览

简要总结

Type 2 diabetes results when the body does not produce enough insulin and/or is unable to properly use the insulin it makes (insulin resistance). This study was undertaken to assess the effects of vildagliptin on insulin sensitivity in people with type 2 diabetes.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
Double

入排标准

年龄范围
21 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Diagnosed with type 2 diabetes at least 3 months prior to screening
  • Blood glucose criteria must be met
  • On stable dose of metformin therapy
  • BMI less than or equal to 39

排除标准

  • Type 1 diabetes, diabetes resulting from pancreatic injury or secondary forms of diabetes
  • Treatment with thiazolidinediones or use of insulin within the previous 3 months
  • Significant illness within 2 weeks prior to dosing
  • High fasting triglycerides as defined by the protocol
  • Other protocol-defined inclusion/exclusion criteria may apply

结局指标

主要结局

Effect on insulin sensitivity at 6 weeks

次要结局

  • Lipolysis rate after 6 weeks of treatment
  • Glucose disposal after 6 weeks of treatment
  • Gluconeogenesis rate after 6 weeks of treatment
  • Plasma free fatty acid concentration after 6 weeks of treatment
  • Hepatic glucose production after 6 weeks of treatment

研究者

发起方
Novartis
申办方类型
Industry

相似试验